Plus   Neg

Stock Alert: Kellogg Edges Up

Shares of Kellogg Company (K) gapped-up more than 4% Thursday morning. The ready-to-eat cereal maker reported upbeat first-quarter results today.

Earnings of $1.00 per share beat the consensus estimate of analysts polled by Thomson Reuters at $0.95.

Net sales were down 3.2% year-on-year at $3.412 billion, on the impact of a recent divestiture. Analysts were expecting $3.39 billion. More than half of the first-quarter sales were attributed to purchases during the global COVID-19 pandemic.

Globally, demand for the Company's products increased significantly in March, as consumers around the world stocked up on packaged foods amidst stay-at-home mandates.

"Our Deploy For Growth strategy has continued to improve the underlying performance of
our business, and our financial condition is solid as we manage through the crisis. In the meantime, we are taking prudent steps to deliver stable and dependable performance now and into the future," said Steve Cahillane, Kellogg Company's Chairman and Chief Executive Officer.

Kellogg stock is currently up 1.85% at $66.07. It has traded in the range of $51.34- $71.05 in the last 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hyundai Motor has launched a new IONIQ brand dedicated to battery electric vehicles, as the automaker is accelerating its efforts to gain a share in the fast-growing global EV market. Under the IONIQ brand, Hyundai plans to introduce three new dedicated electric vehicle models over the next four years. Hyundai is South Korea's largest automaker. Amazon.com, Inc. is in talks with mall operator Simon Property Group, Inc. to use the abandoned anchor departmental stores of JC Penny and Sears at their malls as fulfillment centers, reports said. This is expected to help the e-commerce giant in boosting their last mile delivery, which is the last leg of the delivery process. The U.S. Food and Drug Administration announced the approval of Trevena Inc.'s Olinvyk (oliceridine), a new opioid for intravenous use in hospitals or other controlled clinical settings. Olinvyk is an opioid agonist to manage moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate.
Follow RTT